Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Doncasters Raises $919 Million in NYSE IPO as Aerospace Growth Accelerates 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
Alibaba Shares Fall After Anthropic Alleges Massive AI Model Distillation Campaign 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
Kioxia Targets U.S. Listing as AI Chip Boom Accelerates 
REDWOOD CITY, Calif., Feb. 23, 2016 -- Avinger, Inc., (NASDAQ:AVGR) a developer and manufacturer of image-guided, catheter-based systems for the treatment of peripheral arterial disease (PAD) and pioneer of the lumivascular approach to treating vascular disease, today announced that the company plans to present at the Cowen and Company 36th Annual Health Care Conference in Boston.
Avinger management is scheduled to present on Tuesday, March 8, 2016 at 8:40am ET. Interested parties can access the live audio webcast with accompanying slides from the Events section of Avinger's website at www.avinger.com. The webcast replay will be available after the conclusion of the live presentation for 90 days.
About Avinger, Inc.
Avinger, Inc. is a commercial-stage medical device company that designs, manufactures and sells image-guided, catheter-based systems for the treatment of patients with peripheral arterial disease (PAD). PAD is characterized by a build-up of plaque in the arteries that supply blood to the arms and legs. The company’s mission is to dramatically improve the treatment of vascular disease through the introduction of products based on its lumivascular platform, the only intravascular image-guided system of therapeutic catheters available in this market. Avinger’s current lumivascular products include the Lightbox™ imaging console, the Ocelot™ family of catheters, which are designed to penetrate total arterial blockages, known as chronic total occlusions, or CTOs, and Pantheris™, the first-ever image-guided atherectomy device, designed to precisely remove arterial plaque in PAD patients. For more information, please visit www.avinger.com.
"Avinger," “Pantheris” and the Avinger logo are registered trademarks of Avinger, Inc.
Investor Contact: Leigh Salvo Westwicke Partners Phone: +1 415 513 1281 Email: [email protected]
